Results from a TGen-led international study suggest that SARS-CoV-2 takes advantage of genetic changes among patients with pre-existing lung diseasesContinue reading
Author Archive: AZBio
TGen study suggests a variety of factors beyond age influence reaction time
Reaction time helps measure healthy vs. diseased brains, revealing potential connections tied to the risk of Alzheimer’s disease and dementiaContinue reading
HTG Receives First Commercial Orders for its Planned HTG Transcriptome Panel and Announces the Signing of Two European Early Adopter Program Agreements
TUCSON, Ariz., June 22, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe. HTG has now signed EAP agreements with customers in both the US and Europe and continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.Continue reading
NAU Welcomes a New President
As the 17th president of NAU, José Luis Cruz Rivera has spent time talking with faculty, staff, students and community members, working with university leaders to plan for the fall semester and officially introducing himself and discussing his vision for the university.Continue reading
ASU makes top 10 in U.S. patent rankings for 3rd straight year
For the third consecutive year, ASU is in the top 10 for U.S. patents issued to U.S. universities — and 11th worldwide — according to an annual ranking of the top universities by the National Academy of Inventors and the Intellectual Property Owners Association.Continue reading
2021 CSBI-TEConomy Life Science Workforce Trends Report
The CSBI-TEConomy Life Science Workforce Trends Report reflects Continued Resilience Amidst a Global Pandemic, Adjusting to Remote Work, and Advancing a More Diverse and Inclusive Industry. The report debuted at BIO Digital on June 17, 2021.
Aesthetics Biomedical® Receives FDA Clearance for Vivace® Microneedle RF 2MHz Treatment Setting
The additional FDA clearance provides broad flexibility to choose either 1MHz or 2MHz for treatment
bioSyntagma Launches First Multi-Omic Spatial Platform for Clinical Applications
PHOENIX, June 8, 2021 /PRNewswire/ — bioSyntagma®, Inc unveiled the world’s first high-plex multi-omic spatial workflow designed for clinical samples and diagnostic applications. Compatible with FFPE and large resections up to an inch in size, the Molecular Fingerprint™ (mPrint) technology has been demonstrated to map tumor microenvironments with custom PCR panels, targeted and total sequencing, and spatial imaging at resolutions ranging from single-cell to complex regions of interest. bioSyntagma’s solution is the first to provide a pathway to diagnostic applications with its proprietary spatial-diagnostic machine learning engine that classifies tissues based on tumor microenvironment. Continue reading
Aqualung Therapeutics Plans a Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 Mab) Following Type B FDA Meeting
- Phase 0 trial in ARDS subjects estimated completion by end of 1st QTR 2022
- FDA indicates general agreement on required IND-enabling program for ALT-100 mAb in ARDS patients
- ALT-100 humanized mAb manufacturing initiated and speeding toward GMP completion
HTG Completes Product Design Lock for its Planned Transcriptome Panel and Announces the Signing of the Three Early Adopter Program Collaboration Agreements
TUCSON, Ariz., June 14, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed product design lock for the HTG Transcriptome Panel and announced three Early Adopter Program (EAP) collaborators. HTG continues to progress in its development of a planned transcriptome panel using the HTG EdgeSeq technology. This panel, expected to be called the HTG Transcriptome Panel, will measure approximately 20,000 mRNA targets, with a planned research use only commercial launch in the third quarter of 2021.Continue reading